Investigation of Anticancer Mechanism of alpha1-Adrenoceptor antagonist in Human Prostate Cancer -In vitro and in vivo Studies

• Main Authors: Ssu-Chia Lin, 林思嘉
• Other Authors: Jih-hwa Guh
• Format: Others
• Language: zh-TW
• Published: 2007
• Online Access: http://ndltd.ncl.edu.tw/handle/62234347835662172628

碩士 === 國立臺灣大學 === 藥學研究所 === 95 === Quinazoline-based α1-adrenoceptor antagonists, such as doxazosin and terazosin, have been demonstrated to display anticancer effect in prostate cancer cell lines via a α1-adrenoceptor-independent pathway. In this study, the data showed that several clinically used α1-adrenoceptor antagonists exhibited varied efficacies on the inhibition of PC-3 proliferation by sulforhodamine B (SRB) assay with rank order of prazosin (IC50 = 11.1 μM) > doxazosin (20.6 μM) > phentolamine (58.3 μM) > terazosin (62.6 μM) > tamsulosin (> 100 μM). Similar results were also obtained in other two human prostate cancer cell lines including DU145 and LNCaP. The SRB assay showed that prazosin could display additive effect in combination with doxorubicin, but not camptothecin, mitoxantrone, etoposide, taxol or vincristine. Since prazosin showed the most effective effect, the anticancer mechanism was investigated in this study. By FACScan flow cytometric analysis, the data showed that prazosin induced G2/M arrest and a subsequent increase of hypodiploid phase (apoptosis) of the cell cycle in a time- and concentration-dependent manner. However, the sustained elevation of cyclin A1 and the absence of MPM2 expression suggested that prazosin induced G2- other than mitotic arrest in PC-3 cells. Moreover, prazosin induced an increase of phosphorylation at Ser216 of Cdc25C and a decrease of dephosphorylation at Tyr15 of Cdk1 concomitant with the cytoplasmic sequestration of Cdc25C, suggesting that prazosin induced the inactivation of Cdk1 activity. By comet assay, a short term (one hour) treatment of prazosin was able to cause DNA damage. It could also induce the cleavage of anti-apoptosis members of Bcl-2 family, such as Bcl-2 and Mcl-1, and the activation of caspase cascades. In animal study, the orally administered prazosin (3 and 10 mg/kg) could partly inhibit the PC-3 tumor growth of 50.4 and 64.7%, respectively. Taken together, it is suggested that prazosin is an effective anti-tumor agent both in in vitro and in vivo tests. It induces DNA damage and G2 arrest of the cell cycle and the subsequent apoptosis through an inactivation of Cdk1 activity, the cleavage of anti-apoptosis members of Bcl-2 family and the activation of caspase cascades.